Talk about failing to feel the sting of tight-financing times. With a brain cancer drug derived from scorpion venom aimed for Phase II trials in the second quarter of this year, TransMolecular Inc. (TMI) raised $33.2 million in a Series C round that the company said will be used for multiple clinical and preclinical studies. (BioWorld Today)